Table 2.

The characteristics of the patients with confirmed coronavirus disease 2019 who were on secukinumab therapy

Article	Age/sex	Disease	Duration on secukinumab therapy	Medical history	Presenting COVID-19 symptoms	Treatment	Outcome
Favalli [11]	68/female	PsA	NR	NR	NR	Not hospitalized Treatment details: NR	Managed at home with no any respiratory complication
Di Lernia [24]	73/female	PsA	12–13 months	Hypertension Tachycardia Osteoporosis Fractures Hyperuricemia	Fever Sore throat Mild cough	HQ regimen (800 mg/day for 2 days, followed by 400 mg/day for 5 days)	Recovered, 2 negative RT-PCR tests
Sharmeen [25]	78/male	AS	16 months	Medications:  Amlodipine  Hydrochlorothiazide  Losartan  Nortriptyline  Levothyroxine  Rosuvastatin  Tamsulosin	Fever Severe dry cough Fatigue Myalgia Shortness of breath Frontal headache Lightheadedness	Hospitalized HQ and azithromycin (5 days) Mechanical ventilation	Remained intubated with mechanical ventilation
Haberman [26]	51/male	PsA	NR	Hypertension BMI > 35	Fever Cough Shortness of breath	Hospitalized HQ and azithromycin	Discharged at day 3
Other cases with confirmed COVID-19 (n = 3) did not require hospitalization

PsA psoriatic arthritis, COVID-19 coronavirus disease 2019, RT-PCR reverse transcription-polymerase chain reaction test, AS ankylosing spondylitis, NR not reported, BMI body mass index